177351-56-3

Upstream product

• 136847-16-0 [(4-methoxyphenyl)methylthio]-2-methylpropionic acid 
• 6258-60-2 p-methoxybenzylmercaptan 

Downstream Products

• 136847-17-1 N,N'-bis<2-<(p-methoxybenzyl)thio>-2-methylpropionyl>piperazine 
• 136847-19-3 N,N'-bis<2-<(p-methoxybenzyl)thio>-2-methylpropyl>piperazine 
• 691844-22-1 N,N'-bis<2-<(p-methoxybenzyl)thio>-2-methylpropyl>homopiperazine 
• 158327-22-1 N,N'-bis<2-<(p-methoxybenzyl)thio>-2-methylpropionyl>-2-aminobenzylamine 
• 136847-18-2 N,N'-bis<2-<(p-methoxybenzyl)thio>-2-methylpropionyl>homopiperazine 
• 158327-23-2 N,N'-bis<2-<(p-methoxybenzyl)thio>-2-methylpropyl>-2-aminobenzylamine 

Relevant academic research and scientific papers

HETARYL-SUBSTITUTED HETEROCYCLES

The invention relates to novel compounds of formula (I) in which A, B, W, G and Het have the same designation cited in the description. The invention also relates to several methods for the production of said new compounds and the use thereof as pesticide

Diagnostic radiopharmaceutical compounds (That)

Tetradentate ligands are used to form neutral 99m-technetium complexes which may be useful as radiopharmaceuticals e.g. as brain imaging agents. The ligands have the structure STR1 where n is 2 or 3, m is 0-4, R is H or substituted or unsubstituted C1 -C6 alkyl, provided that one CR2 group adjacent the starred nitrogen atom represents CO and forms with the adjacent N atom, a --CONH-- amide group, Y is unsubstituted or substituted C1 -C6 alkyl, and one of X and X' represents H or a labile thiol protecting group while the other is unsubstituted or substituted C1 -C6 alkyl, alkenyl or alkynyl.

Technetium-99m N,N'-Bis(2-mercapto-2-methylpropyl)-2-aminobenzylamine: Technetium-99m Complexes of a Novel Bis(aminoethanethiol) Ligand

A new N2S2 ligand system, N,N'-bis(2-mercapto-2-methylpropyl)-2-aminobenzylamine, U-BAT, 1, containing uneven amine groups (two amine groups with different pKa values) for complexing VO>3+, was prepared.The reaction of this novel ligand with pertechnetate, in the presence of stannous tartrate as the reducting agent, produces the neutral and lipid-soluble TcVO(U-BAT), TcS2C15H23N2O, 2.However, when the same reaction was carried out at a higher pH, 9-10, and with 30 min of heating (100 deg C), a second neutral but more lipid-soluble complex, TcVO(OU-BAT), TcS2C15H21N2O, 3, was isolated.The X-ray crystallography data of the 99Tc complexes show square pyramidal coordination with N2S2 as the base and the Tc=O in the apical position.Compound 3 can be derived from 2 by an oxidation of the ligand to form an imine.After iv injection into rats, the neutral and lipid-soluble technetium-99m complexes showed significant brain uptake, 1.54 and 1.07percent dose/organ at 2 min for TcVO(U-BAT) and TcVO(OU-BAT), respectively.The novel Tc chemistry of this new ligand system may provide a useful foundation for designing Tc complexes with a built-in redox mechanism.

New conformationally restricted 99mTc N2S2 complexes as myocardial perfusion imaging agents

In developing 99mTc complexes as potential myocardial imaging agents, a new series of ligands based on a conformationally restricted N2S2 system were investigated. Using piperazine or homopiperazine as the starting materia